June 05, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
CLEVELAND — The field of prurigo nodularis has seen landmark updates in the past 5 years, with clinicians expecting more potential treatments in the future, according to a speaker at Cleveland Clinic’s Medical Dermatology Therapy Update IV.Prurigo nodularis (PN), a chronic, debilitating inflammatory skin disease, affects approximately 75,000 adults in the United States. As Healio
June 05, 2026
3 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

Novel Lupus Drugs Continue to Shine in Extended Early Data

New Publication Provides an Unprecedented Look at the Largest Reported Cohort of Nano-Rare Patients Evaluated for Individualized ASO Therapies

Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting

CLEVELAND — After more than a decade with no new medications for chronic spontaneous urticaria, clinicians are beginning to see…

CLEVELAND — For the first time in decades, targeted therapies to treat cutaneous lupus erythematosus are advancing through the…

CLEVELAND — Researchers are uncovering triggers and treatments for cutaneous vasculitis, an inflammatory condition that damages…

Pyoderma gangrenosum is a difficult-to-treat wound disease that may soon have promising new therapies.In this Beneath the Surface…

CLEVELAND — Researchers are beginning to understand the pathogenesis of dermatomyositis, leading to new, targeted therapies for…

DESTIN, Fla. — The anticipated FDA approval of brepocitinib signals an important shift in dermatomyositis management, according…